2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomes
2019
Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients
Stawiarski K, Agboola O, Jacoby D, Bellumkonda L, Ahmad T, Sugeng L, Chen M, McCloskey G, Geirsson A, Anwar M, Bonde P. Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients. The Journal Of Heart And Lung Transplantation 2019, 38: s382-s383. DOI: 10.1016/j.healun.2019.01.974.Peer-Reviewed Original ResearchSerum chloride levelsChloride homeostasisLVAD patientsHeart failureLVAD therapyEnd-stage heart failureCardio-renal axisChronic heart failureStage heart failureChloride levelsLong-term survivalKaplan-Meir plotsLog-rank statisticsL riseCause mortalityLVAD recipientsWorse survivalSingle centerNeurohormonal responsesPrognostic implicationsPrognostic valueLVAD implantsRetrospective analysisGroup ACox model